Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 4:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 70 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: oral metronidazole Clear all
Terminated Phase 4 Interventional Results available

Comparing Oral Versus Parenteral Antimicrobial Therapy

NCT05977868
View directory record Official record
Conditions
Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
Interventions
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 4, 2026, 4:56 AM EDT
Terminated Phase 1 Interventional

Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity

NCT03954990
View directory record Official record
Conditions
Bacterial Vaginoses
Interventions
Metronidazole Oral, Placebo Oral Tablet
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 4, 2026, 4:56 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection

NCT01723059
View directory record Official record
Conditions
Helicobacter Infection
Interventions
Standard Triple Therapy, Sequential Therapy
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 4, 2026, 4:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

NCT04574583
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumors
Interventions
SX-682, M7824, MVA-BN-CV301, recombinant fowlpox viral (FPV)-CV301
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 4, 2026, 4:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine

NCT01418365
View directory record Official record
Conditions
Healthy
Interventions
Metronidazole + MMX Mesalazine/mesalamine placebo, Metronidazole + MMX Mesalazine/mesalamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 4, 2026, 4:56 AM EDT
Terminated Phase 1Phase 2 Interventional

GoldenCareTM for the Treatment of Bacterial Vaginosis

NCT01762670
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
GoldenCare, Metronidazole
Drug
Lead sponsor
CDA Research Group, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Oct 4, 2026, 4:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Responses to Rabies Vaccine in Adults With or Without Antibiotics

NCT03557008
View directory record Official record
Conditions
Rabies Human
Interventions
Rabies Vaccine, Metronidazole, Vancomycin, Neomycin Sulfate
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 4, 2026, 4:56 AM EDT
Terminated Not applicable Interventional Results available

Non-operative Management of Pediatric Appendicitis With an Appendicoltih

NCT02189668
View directory record Official record
Conditions
Appendicitis
Interventions
Antibiotics only (Zosyn then Augmentin)
Drug
Lead sponsor
Peter Minneci
Other
Eligibility
7 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 4, 2026, 4:56 AM EDT
Recruiting Phase 2 Interventional

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

NCT05639647
View directory record Official record
Conditions
Gram-negative Bacterial Infections
Interventions
ATM-AVI, BAT
Drug
Lead sponsor
Pfizer
Industry
Eligibility
9 Months to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 4, 2026, 4:56 AM EDT
Terminated Not applicable Interventional Results available

Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients

NCT04748120
View directory record Official record
Conditions
Covid19, Appendicitis, Cholecystitis, Acute, Cholecystitis; Gallstone, Cholecystitis
Interventions
Operative management, Non-operative management
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 4, 2026, 4:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children

NCT02991937
View directory record Official record
Conditions
Appendicitis
Interventions
Piperacillin/Tazobactam, Surgical Treatment
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 4, 2026, 4:56 AM EDT
Completed Phase 2 Interventional

Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease

NCT06903910
View directory record Official record
Conditions
Parkinson Disease
Interventions
Donepezil (Aricept)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 4, 2026, 4:56 AM EDT
Completed Not applicable Interventional Results available

Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)

NCT01401023
View directory record Official record
Conditions
Diarrhea, Clostridium Difficile
Interventions
Tigecycline
Drug
Lead sponsor
Gary E. Stein, Pharm.D.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
East Lansing, Michigan • Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 4, 2026, 4:56 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo

NCT01426269
View directory record Official record
Conditions
Rosacea
Interventions
Doxycycline, Metronidazole, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Santa Monica, California • Coral Gables, Florida • Corbin, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 4, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

NCT01345175
View directory record Official record
Conditions
Rectal Cancer
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 4, 2026, 4:56 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis

NCT02185456
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
750 mg metronidazole/ 200 mg miconazole vaginal suppository, Standard of care
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2014 · Synced Oct 4, 2026, 4:56 AM EDT
Completed Phase 2 Interventional Results available

Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis

NCT01361048
View directory record Official record
Conditions
Trichomonas Vaginitis
Interventions
oral metronidazole, neo penotran forte, neo penotran forte once a day
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 4, 2026, 4:56 AM EDT
Terminated Phase 4 Interventional Results available

Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients

NCT02200328
View directory record Official record
Conditions
Clostridium Difficile Diarrhea
Interventions
Metronidazole, Placebo
Drug
Lead sponsor
Alison Schneider
Other
Eligibility
55 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 4, 2026, 4:56 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole

NCT06261840
View directory record Official record
Conditions
Trichomonas Vaginitis, Bacterial Vaginitis
Interventions
Metronidazole 500 mg, Secnidazole 2000 MG
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
4
States / cities
Birmingham, Alabama • North Miami, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 4, 2026, 4:56 AM EDT
Terminated Phase 1 Interventional Results available

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

NCT04296942
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer, Hormone Receptor Negative Breast Cancer, Metastatic Breast Cancer
Interventions
Brachyury-TRICOM, Entinostat, M7824, Ado-trastuzumab emtansine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 4, 2026, 4:56 AM EDT
Completed Phase 2 Interventional Results available

Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers

NCT00066066
View directory record Official record
Conditions
Periodontitis, Periodontal Diseases
Interventions
Scaling and root planing, Metronidazole, Amoxicillin, Doxycycline
Procedure · Drug
Lead sponsor
The Forsyth Institute
Other
Eligibility
20 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 4, 2026, 4:56 AM EDT
Completed Phase 2 Interventional

Treating Periodontal Infection: Effects on Glycemic

NCT00016835
View directory record Official record
Conditions
Periodontal Disease, Diabetes Mellitus, Type 2
Interventions
Supra-gingival scaling and placebo, Subgingival scaling and metronidazole, Subgingival scaling and doxycycline
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 4, 2026, 4:56 AM EDT
Completed Phase 4 Interventional Results available

Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

NCT04252742
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
31
States / cities
Long Beach, California • Los Angeles, California • Basalt, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 4, 2026, 4:56 AM EDT
Recruiting Phase 4 Interventional

International Care Bundle Evaluation in Cerebral Hemorrhage Research

NCT06429332
View directory record Official record
Conditions
Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
Interventions
Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care
Other · Diagnostic Test
Lead sponsor
Region Skane
Other
Eligibility
18 Years and older
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 4, 2026, 4:56 AM EDT